Clinical Trial

Intravenous Acetaminophen to Reduce Post-operative Opioid Consumption

Study acronym: ACETAPOP
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated April 11, 2025 (before its estimated August 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
Acetaminophen (Tylenol) is a commonly used medication after surgery to control pain. Tablets for oral use and suppositories for rectal use are the most frequently employed forms of acetaminophen after surgery. Intravenous (IV) acetaminophen is widely used in several countries but is not a standard medication for the adult population in Canada. It is mainly considered when it is impossible to take medication in tablet or suppository form. Opioids (Morphine, Hydromorphone, Oxycodone, etc.) are another class of medications commonly used after surgery for pain management. While they are generally very effective and stronger than acetaminophen or other pain relievers (e.g., ibuprofen/Advil), reducing their use is preferable, as they can cause various side effects such as nausea, dizziness, and dependence. IV acetaminophen may help control pain while also reducing opioid consumption. However, there are few high-quality scientific studies proving the benefits of IV acetaminophen compared to other forms, such as tablets or suppositories. Acetaminophen has been available in Canada for many years and has already been recommended for use in Quebec by the Institut national d'excellence en santé et services sociaux (INESSS) under certain conditions. This study aims to validate its benefits with clear data.
Trial Details
NCT Number NCT06923540
Lead Sponsor Centre hospitalier de l'Université de Montréal (CHUM)
Conditions Post Operative Analgesia, Opioid Consumption, Postoperative, Acetaminophen, Abdominal Surgeries, Post Operative Bowel Dysfunction, Post Operative Nausea and Vomiting, Post Operative Pain Control, Mobility +3 more
Enrollment 140 participants
Start Date 2025-04-28
Primary Completion 2025-08-15 (estimated)
Study Completion 2025-08-15 (estimated)
Updated on ClinicalTrials.gov 2025-04-11